Just as industry wants more certainty built into the generic drug assessments, the US FDA wants more certainty about industry's role, namely when or if sponsors will deal with issues identified in complete response letters.
Industry and agency officials discussed "possible ways to increase industry transparency in its intended response timelines" after an ANDA complete...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?